Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates temozolomide maintain therapeutic efficacy and safety in extensive stage
SCLC who has clinical benefit from etoposide combined Los platinum (EL) scheme in the first
line treatment.